Healthia expects to achieve an EBITDA(u)1(pre AASB16)2 in the range of $38.0m to $39.0m, an increase of between 55.5% and 59.6% on FY22’s EBITDA(u)1(pre AASB16)2 of $24.5m but below previous guidance of EBITDA(u)1(pre AASB16)2 of >$40m4. 

HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Chart Trend not good! . Thinking not a buy at this stage

HLA 30/8/21

Highlights of our FY21 results were:

• $140.4m revenue, +52% increase (FY20: $92.5m)
• $21.5m underlying EBITDA, +62% increase (FY20: $13.2m)
• $8.9m underlying NPATA, +91% increase (FY20: $4.6m)
• 9.1% organic growth (FY20: 5.3%)
• 212 allied health businesses, including +61 added in FY21
• Successful integration of The Optical Company, opening a $3.3 billion market opportunity for the new Eyes & Ears division
• Final fully franked dividend of 2.50 cents per share, bringing the total dividend for FY21 to 4.50 cents per share

I will be presenting these results in further detail at 10.00am AEST this morning at our online investor briefing which I welcome you to attend by clicking below to receive a link to join.

*Acquisition:
During the 2020 Financial Year, Healthia acquired 31 allied health businesses (18 Podiatry Clinics, 9 Physiotherapy Clinics and 4 Hand Therapy Clinics)

Disc' just researching this mob.